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Objectives. To determine the prevalence, the clinical predictors, and the prognostic signiﬁcances of Worsening Renal Function
(WRF) in hospitalized patients with Acute Heart Failure (AHF). Methods. 394 consecutively hospitalized patients with AHF were
evaluated. WRF was deﬁned as an increase in serum creatinine of ≥0.3mg/dL from baseline to discharge. Results. Nearly 11%
of patients developed WRF. The independent predictors of WRF analyzed with a multivariable logistic regression were history
of chronic kidney disease (P = .047), age >75 years (P = .049), and admission heart rates ≥100bpm (P = .004). Mortality or
rehospitalization rates at 1 month, 6 months, and 1year were not signiﬁcantly diﬀerent between patients with WRF and those
without WRF. Conclusion.D i ﬀerent clinical predictors at hospital admission can be used to identify patients at increased risk for
developing WRF. Patients with WRF compared with those without WRF experienced no signiﬁcant diﬀerences in hospital length
of stay, mortality, or rehospitalization rates.
1.Introduction
In the setting of heart failure, baseline renal insuﬃciency is
a common and well-established independent marker of poor
prognosis [1–6]. Worsening Renal Function (WRF) during
the hospitalization for Acute Heart Failure (AHF) occurs
frequently and may also have a prognostic signiﬁcance.
Indeed, several studies have reported that even small changes
inrenalfunctionareassociatedwithlongerlengthofhospital
stay, increased in-hospital costs, higher in-hospital mortality,
higher mortality, and rehospitalization rates at short and
long term [7–12]. However, not all the published infor-
mation agree that WRF is associated with a worse clinical
outcomes[13,14].Moreover,notallthestudieshaveadopted
the same deﬁnition of WRF [7, 8, 10, 11, 13–15] and in most
ofthemonlyshort-termfollowup(in-hospitalcomplications
and 6-months follow-up) was carried on [9–11]. Lastly,
the major part of the results is derived from retrospective
analyses, and in several studies a multivariate analysis was
not performed to identify the independent prognostic value
of WRF [7, 10, 11, 15]. Therefore, the role that WRF plays in
general HF population is still to be better validated.
The goal of this study is to determine the prevalence, the
clinicalpredictors,andtheprognosticsigniﬁcanceofWRFin
a consecutive series of hospitalized patients for AHF.
2.MaterialsandMethods
2.1. Study Population. We enrolled patients consecutively
admitted for AHF at our Institute from October 2002 to May
2008. Criteria for inclusion were exacerbation of previously
documented Heart Failure (HF) or new onset of AHF using
standard Framingham criteria [16]. The only criterion for
exclusionwasthepresenceofterminalnoncardiacillnessthat
could inﬂuence short-term prognosis.
2.2. Study Protocol. The study was approved by the local




discharge. Estimated glomerular ﬁltration rate (eGFR) was
calculated using Modiﬁcation of Diet in Renal Disease
(MDRD) equation. This has been shown to be the best2 International Journal of Nephrology
method for the indirect assessment of renal function in
HF population [17–19]. WRF was deﬁned as an increase
in serum creatinine of ≥0.3mg/dL from baseline to
discharge (WRF(CRE)). This value was chosen because it
has previously been demonstrated to have the maximum
sensitivity and speciﬁcity to predict the prognosis [11].
InordertoverifytheprognosticvalueofWRF,thehazard
ratios for death and rehospitalization were also assessed
for a decline in eGFR ≥20% from baseline to discharge
(WRF(GFR)) [20].
Followup was performed by clinical visits and/or tele-
phone calls at 1 month, 6 months, and 1 year. The
main endpoints were hospital length of stay, death, and
rehospitalization risks.
2.3.StatisticalAnalysis. Continuousvariableswereexpressed
as the arithmetic mean and the standard deviation (SD).
Discrete variables were presented as a percentage. Associa-
tions between WRF and continuous variables were analyzed
using Student’s t-test for normal data and Wilcoxon test for
not normally distributed variables. Discrete Variables were
compared with the use of Chi-square analysis. A forward
stepwise multivariable logistic regression analysis was per-
formed to identify the independent variables predictive of
WRF. All the variables which weresigniﬁcantly diﬀerent (P<
.1) between patients with and without WRF at univariable
analysis were taken into multivariable analysis, but only
retained at an exit signiﬁcance value of P<. 05. Associations
of the development of WRF with the prognostic outcomes
(hospital length of stay, hospitalization, and mortality risks)




3.1. Baseline Characteristics and Prevalence of WRF.
Patients’ characteristics are presented in Table 1. We initially
enrolled in the study 402 consecutive patients. Eight of them
were lost to follow-up and were excluded from the analysis.
No one of the lost to follow-up patients had developed the
WRF during the index hospitalization. Therefore, the study
population consists of 394 consecutive patients. The mean
age of the cohort was 77.9 (SD 10.1) years, with nearly 70%
of the patients over 75 years. The majority of the patients
were male (67.5%). Almost 60% of the total population
had a history of prior hypertension (58.4%), heart failure
(61.7%), and acute coronary syndrome (57.4%). Relatively
highpercentagesofdiabetes(33%)andanemia(42.4%)were
present in the population. The mean ejection fraction was
39.6% (SD 12.2) with 241 patients (61.2%) having EF <
45%. On admission, 159 (40.3%) patients were in NYHA
class IV, 194 (49.2%) patients were in NYHA class III, and
only 41 (10.4%) patients were in NYHA class II. At time
of the admission, more than half of the patients were on
diuretics(72.3%)andonACEinhibitors(54.7%)treatments;
109(27.7%)patientswerereceivingbeta-blockers.Themean
serum creatinine was 1.5 (SD 0.8)mg/dL with 111(28.2%)
of the patients having values >1.5mg/dL. WRF(CRE) and
WRF(GFR) occurred, respectively, in 10.9% and in 11.6% of
the population.
3.2. Predictors of WRF. In the univariable analysis, patients
who experienced WRF(CRE) compared with those without
WRF(CRE) were more likely to be older than 75 years, to
have a history of preexisting Chronic Renal Failure (CRF),
and to have higher heart rate (atrial or sinus arrhythmia
with a heart rate >100bpm). Higher serum creatinine (Scr)
level and lower eGFR value at admission were also found
to be signiﬁcantly associated with the development of WRF.
Moreover, patients with WRF(CRE) were more likely to be
on calcium channel blockers and less likely to be on digoxin
treatment. There were no signiﬁcant diﬀerences in the other
considered variables.
When a multivariable analysis was conducted (results
listed in Table 2), preexisting CRF, admission heart rate
(≥100bpm), and age (>75 years) remained independent risk
factors for the development of WRF(CRE) (resp., P = .047;
.004; .049). Conversely, digoxin treatment resulted to have a
protective eﬀect against WRF(CRE) (P = .024).
3.3. WRF and Prognosis. The mean hospital length of stay
during the index hospitalization was 8.8 ± 4.8 days [median:
7 days; interquartile range(iqr): 6–10] for the whole group.
Patients who develop WRF(CRE) and patients without
WRF(CRE)weresimilarinmeanandmedianhospitallength
of stay (resp., mean: 8.5 ± 4.3 days; median: 7 days; iqr: 6–
10; Versus mean: 8.9 ± 4.9 days; median: 7 days; iqr: 6–10;
P = .64). Patients with and patients without WRF(GFR)
experienced no signiﬁcant diﬀerences in hospital length of
stay (resp., mean: 8.0 ± 3.6 days; median: 7 days; iqr: 5–10;
Versus mean: 8.9±5days;median:7days;iqr:6–10;P = .29).
There were no statistically signiﬁcant diﬀerences in
rehospitalization risk between patients with WRF(CRE) and
patients without WRF(CRE) at either 1 month, 6 months,
or 12 months (results shown in Table 3). Patients with
WRF(CRE) experienced no signiﬁcantly higher risk of death
at 1-, 6-, and 12-month followup (Table 3).
Similar results were observed when the WRF(GFR)
deﬁnition was adopted (results shown in Table 4).
The combined endpoint death/rehospitalization was
considered for the construction of Kaplan-Meier survival-
free curves of patients with and without WRF(CRE). As it
is possible to observe in Figure 1, the two curves were almost
similar (log-rank test: P = .947).
4. Discussion
S e v e r a lp r e v i o u ss t u d i e sh a v er e p o r t e dar e l a t i v e l yh i g h
prevalence of WRF (around 25%) among patients hospital-
ized with acute heart failure [10, 12, 14, 21]. In our study, the
prevalence of WRF is lower (11%). This is probably due to
thefactthatinourstudypatientswithatransitoryincreasein
ScrordecreaseineGFR,whichdidnotpersistatthemoment
of discharge, were not considered as WRF-patients.International Journal of Nephrology 3
Table 1: Characteristics at admission of the whole population and of patients with and without WRF (CRE).
Total WRF absent WRF present P-value
(n = 394) (n = 351) (n = 43)
Demographics
Age (mean, SD) 77.9 (10.1) 77.8 (10.3) 79.2 (8.4) .380
Age > 75 years 274 (69.5) 239 (68.1) 35 (81.4) .074
Males 266 (67.5) 236 (67.2) 30 (69.8) .738
Medical history
Prior heart failure 243 (61.7) 218 (62.1) 25 (58.1) .613
Diabetes 130 (33.0) 108 (30.8) 12 (27.9) .700
Valvular disease 108 (27.4) 99 (28.2) 9 (20.9) .313
COPD 122 (30.9) 111 (31.6) 11 (25.6) .418
Hypertension 230 (58.4) 201 (57.3) 29 (67.4) .201
Peripheral vascular disease (PVD) 74 (18.8) 67 (19.1) 7 (16.3) .656
Previus acute coronary syndrome 226 (57.4) 204 (58.1) 22 (51.2) .384
Prior renal failure 95 (24.1) 76 (21.6) 19 (44.2) .001
Clinical and laboratory parameters
Systolic blood pressure, mm Hg (mean, SD) 132 (25.5) 131 (25.1) 137 (29.1) .138
Systolic blood pressure >160mm Hg 43 (10.9) 36 (10.3) 7 (16.3) .230
Serum creatinine, mg/dL (mean, SD) 1.5 (0.8) 1.47 (0.8) 1.71 (0.9) .066
Creatinine > 1,5mg/dL 111 (28.2) 92 (26.2) 19 (44.2) .013
GFR, mL/min (mean, SD) 54 (23.5) 55 (22.8) 51 (28.4) .070
GFR < 60mL/min 239 (60.7) 207 (59.0) 32 (74.4) .055
Sodium, mEq/L (mean, SD) 140 (4.4) 140 (4.5) 140 (3.5) .854
Potassium, mEq/L (mean, SD) 4.0 (0.6) 4.0 (0.6) 3.9 (0.6) .219
Glycemia, mg/dL (mean, SD) 76 (73.0) 78 (74.6) 58 (56.6) .114
Haemoglobin, gr/dL (mean, SD) 12.6 (6.5) 12.7 (1.8) 12.1 (6.9) .387
Anaemia (hemoglobin <12gr/dL) 167 (42.4) 147 (41.9) 20 (46.5) .562
Haematocrit (mean, SD) 38 (6.1) 39 (6.2) 38 (5.2) .502
Azotemia, mg/dL (mean, SD) 46 (50.0) 45.5 (49.1) 50.2 (60.5) .561
NYHA class (mean, SD) 3.3 (0.7) 3.3 (0.6) 3.3 (0.7) .778
NYHA class III-IV 353 (89.6) 316 (90.0) 37 (86.0) .420
KILLIP (mean, SD) 2.4 (0.6) 2.3 (0.6) 2.4 (0.6) .363
Doppler echocardiography
Ejection fraction (mean, SD) 39.6 (12.2) 39.5 (12.2) 39.7 (12.4) .942
Ejection fraction <45% 241 (61.2) 215 (61.3) 26 (60.5) .869
Left atrial size, mm (mean, SD) 46.3 (7.3) 46.4 (7.5) 45.2 (6.0) .343
Left ventricular size, mm (mean, SD) 58.5 (9.5) 58.4 (10.0) 58.1 (6.7) .982
Left atrial dilatation 232 (58.9) 211 (60.1) 21 (48.8) .279
Left ventricular dilatation 265 (67.3) 237 (67.5) 28 (65.1) .880
Elettrocardiogram
LBBB 45 (11.4) 40 (11.4) 5 (11.6) .960
Heart rate, bpm (mean, SD) 85.3 (17.0) 85 (17.0) 88 (16.3) .276
Heart rate ≥ 100bpm 80 (20.3) 64 (18.2) 16 (37.2) .003
Atrial ﬁbrillation 164 (41.6) 149 (42.4) 15 (34.9) .342
Medical treatments
Aldosterone antagonists 88 (22.3) 76 (21.6) 12 (27.9) .352
Diuretics 285 (72.3) 255 (72.5) 30 (69.8) .690
Beta-blockers 109 (27.7) 98 (27.9) 11 (25.6) .746
Calcium channell blockers 60 (15.3) 49 (14.0) 11 (25.6) .045
ACE inhibitors 215 (54.7) 190 (54.1) 25 (58.1) .618
ARBs 37 (9.4) 30 (8.5) 7 (16.3) .101
Statins 46 (11.7) 40 (11.4) 6 (14.0) .865
ASA 163 (41.4) 143 (40.7) 20 (46.5) .468
Warfarin 101 (25.6) 91 (25.9) 10 (23.3) .705
Nitrates 144 (36.5) 133 (37.9) 11 (25.6) .114
Digoxin 99 (25.1) 95 (27.1) 4 (9.3) .006
ACE: angiotensin-converting enzyme; ARBs: angiotensin receptor blockers; ASA: acetylsalycilic acid; LBBB: left bundle branch block; COPD: chronic
obstructive pulmunary disease; NYHA: New York Health Association.4 International Journal of Nephrology
Table 2: Predictors of WRF (CRE): multivariable analysis.
Predictors Odds ratio 95% CI P-value
Age > 75 years 2.34 1.00–5.46 .049
Calcium channel blockers 1.53 0.68–3.44 .300
Creatinine > 1,5mg/dL 0.90 0.33–2.50 .840
Digoxin 0.29 0.10–0.85 .024
Prior renal failure 2.80 1.01–7.79 .047
Heart rate ≥ 100bpm 2.89 1.40–5.94 .004
CI: Conﬁdence Interval.
Table 3: Association of WRF (CRE) with mortality and rehospital-
izations risks.
HR 95% CI P-value
Mortality
1 month 1.01 0.13–8.07 .99
6 months 0.80 0.32–1.99 .63
12 months 1.03 0.49–2.15 .94
Rehospitalization
1 month 1.32 0.51–3.38 .56
6 months 1.00 0.59–1.70 .99
12 months 1.02 0.63–1.63 .95
CI: Conﬁdence Interval.




1 month 0.93 0.12–7.43 .94
6 months 0.89 0.38–2.08 .79
12 months 1.09 0.54–2.12 .81
Rehospitalization
1 month 1.21 0.47–3.01 .69
6 months 0.82 0.47–1.43 .48
12 months 0.89 0.55–1.43 .63
CI: Conﬁdence Interval.
The mechanisms which may cause WRF in patients
with HF are multiple and are not completely understood
[22] .S e v e r a lp r e d i c t o r so fW R Fh a v eb e e nr e p o r t e di n
the literature. One of the most acknowledged predictors is
renal dysfunction either as a preexisting renal disease or as
admission renal failure [8, 9, 13]. In a retrospective study
carried on by Forman et al [10] on more 1000 patients,
history of prior chronic heart failure, diabetes, systolic blood
pressure >160mmHg, and serum creatinine >1.5mg/dL
wereidentiﬁed asthemostimportant predictors ofWRFand
used to elaborate a score to stratify the risk of developing
WRF. Other reported important risk factors of WRF were:
advanced age [7, 21], high systolic blood pressure [10, 14],
diabetes [8, 10, 14], pulmonary edema [13], NYHA class [8],
ejection fraction [8], use of high doses of furosemide [8, 9],





































Figure 1: Kaplan-Meire hospitalization and morality free survival
curves for patients with and without WRF.
In our study, we report that the history of preexisting
renal failure is one of the strongest independent predictors
of WRF. The age was found to be another independent
predictor of WRF. Patients who are >75 years old were more
likely to develop WRF.
In the univariable analysis, baseline serum creatinine
and baseline eGFR were associated with WRF; however
these links disappeared when the multivariable analysis were
conducted. Although the results of some studies [10, 13]
are not consistent with these ﬁndings, in the ESCAPE study
baseline renal insuﬃciency was not predictive of WRF even
in the univariable analysis [14], and similar results were
observed in the prospective study of Metra et al. [8].
In our investigation, digoxin use was shown to have a
protective eﬀect against WRF. This result has not been re-
ported previously. The eﬀect does not disappear on mul-
tivariable analysis. Since the small number of patients on
digoxin use, this observation is likely to be due only to
chance.
Heartrate>100bpmwasanotherindependentriskfactor
of WRF that was not previously reported. This ﬁnding may
be due to an underlying more severe cardiac disease or to an
underuse of medications in these patients.
Worsening renal function during the hospitalization for
acute heart failure has been shown to be associated with
lengthier hospitalization. However, in our study, the patients
with WRF had almost equal mean hospital length of stay to
those who did not develop WRF.
Similar short- and long-term rehospitalization and mor-
tality rates were found in patients with and without WRF.
Similar ﬁndings were observed adopting both deﬁnitions of
WRF (WRF(CRE) and WRF(GFR)) to assess the prognostic
signiﬁcance of WRF. These data are in agreement with
the results reported in a European multicenter prospective
study (POSH study) [13] and in the ESCAPE study [14].
On the other hand, several studies have reported that evenInternational Journal of Nephrology 5
small changes in serum creatinine during the hospital-
ization for acute heart failure are associated with higher
rehospitalization risk and mortality rate. These conﬂicting
results highlight the need of a better comprehension of the
prognostic signiﬁcances of WRF in patients with AHF. The
fear of WRF may have important clinical consequences,
since the physicians could tend to reduce diuretics dosages
and to underuse important life-prolonging drugs such as
aldosterone antagonists and ACE inhibitors.
Further prospective studies are needed to elucidate
whether WRF, in the setting of AHF, is a justiﬁed fear or
just a marker of intrinsic renal disease that is inevitable in
patients with several risk factors.
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